GDXJ vs IBB
VanEck Junior Gold Miners ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.52% for GDXJ.
- • GDXJ pays a higher dividend yield (2.27%).
Side-by-side metrics
| Metric | GDXJ | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.52% | 0.44% |
Dividend yield Trailing 12-month yield. | 2.27% | 0.23% |
AUM Assets under management — bigger funds are typically more liquid. | $8.72B | $7.95B |
YTD return | 7.88% | 3.10% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.86 | 0.74 |
P/E ratio | 17.66 | 23.72 |
Last price | $122.42 | $170.10 |
Inception | — | — |
Issuer | VanEck | iShares |
GDXJ top holdings
| AGI.TO | Alamos Gold Inc Class A | 6.81% |
| EQX.TO | Equinox Gold Corp Ordinary Shares Class A | 6.40% |
| CDE | Coeur Mining Inc | 6.39% |
| EVN.AX | Evolution Mining Ltd | 6.13% |
| EDV.L | Endeavour Mining PLC | 5.87% |
| PE&OLES.MX | Industrias Penoles SAB de CV | 2.85% |
| AG.TO | First Majestic Silver Corp | 2.58% |
| HL | Hecla Mining Co | 2.20% |
| IMG.TO | Iamgold Corp | 2.14% |
| LUG.TO | Lundin Gold Inc | 2.03% |
IBB top holdings
| AMGN | Amgen Inc | 7.37% |
| GILD | Gilead Sciences Inc | 7.32% |
| VRTX | Vertex Pharmaceuticals Inc | 7.21% |
| REGN | Regeneron Pharmaceuticals Inc | 6.55% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.71% |
| ARGX | argenx SE ADR | 3.33% |
| INSM | Insmed Inc | 2.70% |
| BIIB | Biogen Inc | 2.67% |
| NTRA | Natera Inc | 2.40% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.27% |
About GDXJ
GDXJ (VanEck Junior Gold Miners ETF) is Small and mid-cap gold and silver mining companies. Managed by VanEck, the fund carries $8.7B in assets under management, an expense ratio of 0.52%, a dividend yield of 2.27%. Its largest holding is Alamos Gold Inc Class A (AGI.TO), which represents 6.8% of the portfolio. Basic Materials is the fund's largest sector exposure at 100.0%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $7.9B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.23%. Its largest holding is Amgen Inc (AMGN), which represents 7.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.